We are recruiting to several national pandemic studies looking at the impact of viruses in the population:
This study aims to compare several different treatments that may be useful for patients with COVID-19. These treatments have been recommended for testing by the expert panel that advises the Chief Medical Officer in England. Some are tablets and some are injections. Although these treatments show promise, nobody knows if any of them will turn out to be more effective in helping patients recover than the usual standard of care in our hospital (which all patients will receive).
Principle investigator: Dr Dina Mansour. You can contact the main trial research nurses:
Research midwives can be contacted at firstname.lastname@example.org.
Dr Anne Dale, consultant paediatrician can be contacted at email@example.com for the paediatric arm.
ISARIC are an international consortium which investigates novel pathogens causing severe acute respiratory illness (SARI) and emerging infections of public health importance. ISARIC members working with the NIHR Clinical Research Network (NIHR CRN) have developed a protocol that allows the rapid study of disease caused by any pathogen of public health importance.
Principle investigator: Dr Vanessa Linnett.
UKOSS Pandemic Influenza
An observational study collecting anonymous data aiming to determine details around hospitalisation and outcomes for mother and baby, where mothers have been admitted with COVID-19.
Please contact research midwives firstname.lastname@example.org for further information.
Genetics of Susceptibility & Mortality in Critical Care. This is a University of Edinburgh research study to identify genetic predisposition to specific life-threatening illness following infection with bacteria/viruses. A blood sample will be taken from patients that fulfil the criteria and their DNA will be looked at in detail to identify factors that make them susceptible to these infections. This will enable us to prioritise therapeutic targets for future cohorts.
This study is looking at acute (recent onset) respiratory (nose, throat and chest) infections, one of the most common infectious diseases across Europe. The study involves a comparison between adults who visit their GP due to respiratory infections and adults who need hospitalisation for similar infections. This will allow us to study why some people develop more severe symptoms. The results of this study can help us to improve the prevention, treatment and care of these infections and hopefully reduce the number of severe cases.
This study is looking at whether severe infection be prevented in Covid-19. For a small minority, Covid-19 can result in serious disease. The immune system can be affected so that it produces an overactive response which can lead to life-threatening multi-organ failure. The purpose of this trial is to determine the best way to treat patients with COVID-19 infection by comparing different treatments which act on the immune system, with the aim of reducing severe symptoms and therefore the number of Intensive Care Unit (ICU) admissions in hospital.
This study looks at using single drugs, a combination of drugs or usual treatment to see which benefits patient groups best.
The study team are looking to:
- determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death.
- identify the pharmacodynamic effects of therapies on biomarkers known to be associated with progression of COVID-19 related complications.
- determine if a specific intervention reduces severity of disease.
- assess the safety and efficacy of the different arms.
We are recruiting patients aged 18 or over who have been admitted to hospital with COVID-19.
REMAP-CAP is an international (15 countries) adaptive platform trial in community acquired pneumonia, that was specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients. In addition to recruiting patients with community acquired pneumonia who have been admitted to critical care, we are also recruiting patients with COVID-19 to understand optimal treatment strategies.
As COVID-19 is a new disease, this study aims to identify whether there are longer-term health problems of COVID-19 for those who were hospitalised.
The study team want to understand:
- why some people recover more quickly than others.
- why some patients develop other health problems later.
- which treatments received in hospital or afterwards were helpful.
- how we can improve care of patients after they have been discharged from hospital.
We are recruiting patients who have been discharged from hospital following COVID-19 to study short (0- 6months), medium (6-12 months) and long term (12 months +) effects of the disease.
The principal investigator is Lorraine Pearce, who can be contacted at email@example.com. The main trial research nurses are firstname.lastname@example.org, email@example.com, firstname.lastname@example.org or email@example.com. Data manager is firstname.lastname@example.org.
Psychological impact of COVID-19
The aim of this study is to assess the short and long-term psychological impact on patients who have survived an admission to intensive care due to COVID-19, and identify possible predictors of anxiety, depression and trauma symptoms in this patient group. A questionnaire will be sent to patients after three month of hospital admission. The results will help to expand services as necessary and support ICU survivors properly to help them regain their quality of life and return to working and contributing to society.
CCP Cancer UK
CCP-CANCER UK aims to provide information that would educate as well as help inform current practice and development of guidelines globally with regard to COVID-19 infection in cancer patients, in both haematological and solid malignancies. This is a prospective observational cohort study specifically for cancer patients which will be recruited alongside the Principal ISARIC CCP-UK protocol in the UK. Patients enrolled if they have proven COVID-19 and a diagnosis of cancer who are enrolled into any Tier of the Principal CCP-UK protocol. Principal investigator is Dr Fiona McDonald. You can contact clinical trials officer email@example.com or firstname.lastname@example.org. The research nurse is email@example.com and data managers are firstname.lastname@example.org and email@example.com.